메뉴 건너뛰기




Volumn 30, Issue 3, 2010, Pages 963-966

Severe Intoxication with Methotrexate Possibly Associated with Concomitant Use of Proton Pump Inhibitors

Author keywords

Drug drug interaction; Glucarpidase; Methotrexate; Proton pump inhibitor

Indexed keywords

CARBOXYPEPTIDASE G2; CREATININE; ESOMEPRAZOLE; LANSOPRAZOLE; METHOTREXATE; OMEPRAZOLE; PANTOPRAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

EID: 77951033350     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (36)

References (17)
  • 1
    • 0013065232 scopus 로고    scopus 로고
    • Antifolates
    • Chabner BA, Longo DL (eds.). Philadelphia, Lippincott Williams & Wilkins
    • Messmann RA and Allegra CJ: Antifolates. In: Cancer Chemotherapy and Biotherapy. Chabner BA, Longo DL (eds.). Philadelphia, Lippincott Williams & Wilkins, pp. 139-184, 2001.
    • (2001) Cancer Chemotherapy and Biotherapy , pp. 139-184
    • Messmann, R.A.1    Allegra, C.J.2
  • 2
    • 0022613399 scopus 로고
    • Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen
    • Thyss A, Milano G, Kubar J, Namer M and Schneider M: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1: 256-258, 1986.
    • (1986) Lancet , vol.1 , pp. 256-258
    • Thyss, A.1    Milano, G.2    Kubar, J.3    Namer, M.4    Schneider, M.5
  • 4
    • 33748065311 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between methotrexate and piperacillin/ tazobactam resulting in prolonged toxic concentration of methotrexate
    • Zarychanski R, Wlodarczyk K, Ariano R and Bow E: Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentration of methotrexate. J Antimicrob Chemother 58: 228-230, 2006.
    • (2006) J Antimicrob Chemother , vol.58 , pp. 228-230
    • Zarychanski, R.1    Wlodarczyk, K.2    Ariano, R.3    Bow, E.4
  • 6
    • 0036218554 scopus 로고    scopus 로고
    • Changes in plasma protein binding have little clinical relevance
    • Benet L and Hoerner BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71: 115-121, 2002.
    • (2002) Clin Pharmacol Ther , vol.71 , pp. 115-121
    • Benet, L.1    Hoerner, B.A.2
  • 9
    • 0037157552 scopus 로고    scopus 로고
    • Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate
    • Tröger U, Stötzel B, Martens-Lobenhoffer J, Gollnick H and Meyer FP: Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br Med J 324: 1497, 2002.
    • (2002) Br Med J , vol.324 , pp. 1497
    • Tröger, U.1    Stötzel, B.2    Martens-Lobenhoffer, J.3    Gollnick, H.4    Meyer, F.P.5
  • 11
    • 46149091491 scopus 로고    scopus 로고
    • Interaction between methotrexate and omeprazole in an adolescent with leukemia: A case report
    • Bauters TGM, Verlooy J, Robays H and Laureys G: Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci 30: 316-318, 2008.
    • (2008) Pharm World Sci , vol.30 , pp. 316-318
    • Bauters, T.G.M.1    Verlooy, J.2    Robays, H.3    Laureys, G.4
  • 12
    • 58149127453 scopus 로고    scopus 로고
    • Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy
    • Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y and Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67: 44-49, 2009.
    • (2009) Br J Clin Pharmacol , vol.67 , pp. 44-49
    • Suzuki, K.1    Doki, K.2    Homma, M.3    Tamaki, H.4    Hori, S.5    Ohtani, H.6    Sawada, Y.7    Kohda, Y.8
  • 13
    • 4143142207 scopus 로고    scopus 로고
    • Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions
    • Breedveld P, Zelcer N, Pluim D, Sönmezer Ö, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P and Schellens JHM: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64: 5804-5811, 2004.
    • (2004) Cancer Res , vol.64 , pp. 5804-5811
    • Breedveld, P.1    Zelcer, N.2    Pluim, D.3    Sönmezer, Ö.4    Tibben, M.M.5    Beijnen, J.H.6    Schinkel, A.H.7    Van Tellingen, O.8    Borst, P.9    Schellens, J.H.M.10
  • 14
    • 33745647522 scopus 로고    scopus 로고
    • Understanding and managing methotrexate nephrotoxicity
    • Widemann BC and Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 11: 694-703, 2006.
    • (2006) Oncologist , vol.11 , pp. 694-703
    • Widemann, B.C.1    Adamson, P.C.2
  • 16
    • 0033023027 scopus 로고    scopus 로고
    • Omeprazole does not alter plasma methotrexate clearance
    • Whelan J, Hoare D and Leonard P: Omeprazole does not alter plasma methotrexate clearance. Cancer Chemother Pharmacol 44: 88-89, 1999.
    • (1999) Cancer Chemother Pharmacol , vol.44 , pp. 88-89
    • Whelan, J.1    Hoare, D.2    Leonard, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.